Nestle SA

Nestlé SA is a nutrition, health, and wellness company, which engages in the business of manufacturing, supplying, and producing prepared dishes and cooking aids, milk-based products, pharmaceuticals and ophthalmic goods, baby foods, and cereals. It operates through the following segments: Zone North America; Zone Europe; Zone Asia, Oceania, and Africa; Zone Latin America; Zone Greater China; Nestlé Health Science; and Nespresso. The company was founded by Henri Nestlé in 1866 and is headquartered in Vevey, Switzerland.

Aimmune Therapeutics

Nestlé completes acquisition of Aimmune Therapeutics

Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic.

Aimmune shareholders accept $2 billion Nestle tender offer

Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.

British American Tobacco

Novo Nordisk

Novartis

Roche Holding AG

SAP SE

Sanofi

Unilever

Vanguard FTSE Developed Markets ETF

Leading wealth managers including BlackRock, Merrill Lynch and Putnam are advising their clients to invest in foreign stocks to take advantage of better values overseas. And the market's best European stocks are one such store of value-priced diversification.

10 Best European Stocks for an Income-Rich Recovery

ST. LOUIS, Sept. 30, 2020 /PRNewswire/ -- Today, Nestlé Purina PetCare announced an estimated $450 million investment to open a new factory in Eden, North Carolina, to meet increasing demand for its high-quality, nutritious pet foods. This expansion is part of a broader growth plan for...

Nestlé Purina PetCare Plans to Open New Factory in North Carolina to Meet Growing Pet Food Demand

Demand for plant-based foods has picked up during the coronavirus crisis as consumers try to eat more healthily and problems at some factories have hit meat supplies, the head of Swiss food giant Nestle said on Monday.

Pandemic boosting demand for plant-based foods, Nestle says

Keurig Dr Pepper Inc

Restaurant Brands

J. M. Smucker

These coffee stocks are the best for value, profitability, and momentum for Q4 2020.

Top Coffee Stocks for Q4 2020

Nestlé commences tender offer for Aimmune Therapeutics, Inc.

Amazon

Covetrus Inc

Merck

Zoetis

Despite the economic challenges of the pandemic, Americans are spoiling their pets. Profit from that hot market with these top growth stocks.

5 Hot Growth Stocks to Buy With Fido in Mind

Spending on pets in the US continues to rise. According to the APPA, spending for 2020 is projected to come in at $99 billion, up from $94 billion in 2019 and $90 billion in 2018, representing a climb of 9.4% in just two years.

People Always Spend on Their Pets

Nestle will do more acquisitions, also big ones, the food giant's chief financial officer said on Wednesday.

Nestle likely to do more big acquisitions: CFO

Nestle has increased the share of recyclable or reusable plastics to package its products to 87%, making progress toward its 100% goal by 2025, and gave examples of innovation to cut plastic waste in a media briefing on Monday.

Nestle on track to meet sustainable packaging goal

These drugmakers are in the sweet spot to provide market-beating returns.

2 Mid-Cap Healthcare Stocks to Buy Now

BRIDGEWATER, N.J., Sept. 3, 2020 /PRNewswire/ -- Nestlé Health Science, a globally recognized leader in the field of nutritional science today announced the launch of MYAACD.org, an educational platform to drive awareness of Age-Associated Cellular Decline (AACD).

Nestlé Health Science Launches Educational Platform To Build Awareness Of The Role Of Age-Associated Cellular Decline (AACD) In The Aging Process

Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.

Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up

Swiss giant adds third drug to its portfolio this year

Nestle Shells Out $2 Billion for Peanut Allergy Med

Utz Brands

Stock Markets Celebrate a Strong August; Nestle's Hungry for Aimmune as Utz Feeds IPO Investors

Aimmune Therapeutics' news of its agreement with Nestle regarding its food allergy treatment has AIMT stock soaring way higher on Monday.

Aimmune Therapeutics News: Why AIMT Stock Is Skyrocketing Today

Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares more than doubled to start out the week after reports surfaced that the company would be acquired by Nestle Health Sciences, a subsidiary of the Nestle.

Are Aimmune Shareholders Getting Enough in the Buyout?

Nestlé is buying the maker of a peanut allergy drug for children for $2.6 billion as it deepens its focus into health care and nutrition.

Nestle is paying $2.6 billion for a company that treats peanut allergies

Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment.
Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment.

Here’s why Nestlé is buying a peanut-allergy company for $2.6B

New York, New York--(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/62871_5167b93204a2486d_001full.jpgTo: All Persons or Entitie

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Aimmune Therapeutics, Inc. to Nestlé S.A.

Swiss food giant Nestle early Monday announced an agreement to buy Aimmune Therapeutics, the maker of the only approved drug to treat peanut allergies, for $2.6 billion. AIMT stock soared.

Nestle To Buy Peanut Allergy Treatment Maker Aimmune For $2.6 Billion

Nestle is gobbling up the peanut allergy drugmaker Aimmune Therapeutics for a cool $2.6 billion.

Why Aimmune Therapeutics Stock Is Soaring Today

The world’s largest consumer products company, Nestlé S.A., has agreed to acquire Aimmune Therapeutics Inc.

News for Nestle SA Stock (NSRGY)